Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported disease

Goldstein, 2001, Familial Hypercholesterolemia, 2863 Abifadel, 2003, Mutations in PCSK9 cause autosomal dominant hypercholesterolemia, Nat Genet, 34, 154, 10.1038/ng1161 Cuchel, 2014, Homozygous familial hypercholesterolemia: New insights and guidance for clinicians to improve detection and clinical management; a position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society, Eur Heart J, 35, 2146, 10.1093/eurheartj/ehu274 Raal, 2012, Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment, Atherosclerosis, 223, 262, 10.1016/j.atherosclerosis.2012.02.019 Sjouke, 2015, Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome, Eur Heart J, 36, 560, 10.1093/eurheartj/ehu058 Hopkins, 2015, Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody, Circ Cardiovasc Genet, 8, 823, 10.1161/CIRCGENETICS.115.001129 Rauh, 1991, Identification of a heterozygous compound individual with familial hypercholesterolemia and familial defective apolipoprotein B-100, Klin Wochenschr, 69, 320, 10.1007/BF01644767 Benlian, 1996, Phenotypic expression in double heterozygotes for familial hypercholesterolemia and familial defective apolipoprotein B-100, Hum Mutat, 7, 340, 10.1002/(SICI)1098-1004(1996)7:4<340::AID-HUMU8>3.0.CO;2-C deCampo, 2001, A novel splice-site mutation in intron 7 causes more severe hypercholesterolemia than a combined FH-FDB defect, Atherosclerosis, 157, 524, 10.1016/S0021-9150(01)00535-4 Raal, 1997, Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects, Atherosclerosis, 129, 97, 10.1016/S0021-9150(96)06007-8 Rubinsztein, 1993, Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100, Arterioscler Thromb, 13, 1076, 10.1161/01.ATV.13.7.1076 Tai, 2001, Compound heterozygous familial hypercholesterolemia and familial defective apolipoprotein B-100 produce exaggerated hypercholesterolemia, Clin Chem, 47, 438, 10.1093/clinchem/47.3.438 Taylor, 2010, A double heterozygote for familial hypercholesterolaemia and familial defective apolipoprotein B-100, Ann Clin Biochem, 47, 487, 10.1258/acb.2010.010089 Pisciotta, 2006, Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia, Atherosclerosis, 186, 433, 10.1016/j.atherosclerosis.2005.08.015 Bertolini, 2013, Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy, Atherosclerosis, 227, 342, 10.1016/j.atherosclerosis.2013.01.007 Huijgen, 2010, Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia, Hum Mutat, 31, 752, 10.1002/humu.21258 Goldstein, 1974, Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia, J Biol Chem, 249, 5153, 10.1016/S0021-9258(19)42341-7 Innerarity, 1987, Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding, Proc Natl Acad Sci U S A, 84, 6919, 10.1073/pnas.84.19.6919